Stay updated on Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial

Sign up to get notified when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A service alert has been added regarding planned maintenance on July 26th, indicating that most services will be unavailable for over 12 hours starting at 6 AM EDT.
    Difference
    4%
    Check dated 2025-07-10T05:15:30.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.
    Difference
    5%
    Check dated 2025-07-03T03:17:01.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    4%
    Check dated 2025-06-18T21:03:55.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.1 to v2.16.2.
    Difference
    0.3%
    Check dated 2025-06-11T19:46:31.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    6%
    Check dated 2025-05-28T10:13:56.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    The content regarding 'Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)' has been completely removed from the page.
    Difference
    0.3%
    Check dated 2025-05-21T07:57:18.000Z thumbnail image

Stay in the know with updates to Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.